Fecal Microbiota Transplantation. Techniques, Applications, and Issues

Gastroenterology Clinics of North America

Volumn 41, Issue 4, 2012, Pages 781-803

  Borody, Thomas Julius ^a   Campbell, Jordana ^a  

^a Centre for Digestive Diseases   (Australia)

Author keywords

Clostridium difficile; Fecal microbiota transplantation; Microbiome; Microbiota; Probiotics; Ulcerative colitis

Indexed keywords

ANTIBIOTIC AGENT; COLCHICINE; ENEMA; FIDAXOMICIN; METRONIDAZOLE; PENICILLIN G; RIFAXIMIN; STREPTOMYCIN; SUCCINYLSULFATHIAZOLE; TETRACYCLINE; VANCOMYCIN;

ANOREXIA NERVOSA; BIOLOGICAL THERAPY; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; COLONOSCOPE; CONSTIPATION; CROHN DISEASE; DIARRHEA; ENTERITIS; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INTESTINE FLORA; MEDICAL EXPERT; MEDICAL LITERATURE; MORTALITY; MULTIPLE SCLEROSIS; MYOCLONUS DYSTONIA; NASOGASTRIC TUBE; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; PSEUDOMEMBRANOUS COLITIS; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; CLOSTRIDIUM DIFFICILE; COLITIS, ULCERATIVE; DIARRHEA; ENEMA; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; HUMANS; INTUBATION, GASTROINTESTINAL; METAGENOME;

EID: 84867959193     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2012.08.008     Document Type: Review

References (103)

1. Jarvis W.R., Schlosser J.A., Jarvis A.A., et al. National point prevalence of Clostridium difficile in US health care facility inpatient. Am J Infect Control 2008, 37:263-270.
2. Andrews P., Borody T.J., Shortis N.P., et al. Bacteriotherapy for chronic constipation-long term follow-up. Gastroenterology 1995, 108:A563.
3. Borody T.J., Leis S., Campbell J., et al. Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol 2011, 106:S352.
4. Borody T.J., Campbell J., Torres M., et al. Reversal of idiopathic thrombocytopenia purpura (ITP) with fecal microbiota transplantation (FMT). Am J Gastroenterol 2011, 106:S352.
5. Borody T.J., Warren E.F., Leis S., et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003, 37(1):42-47.
6. Bennet J.D., Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989, 1:164.
7. Bakken J.S., Borody T.J., Brandt L.J., et al. Treating Clostridium difficile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011, 9:1044-1049.
8. Borody T.J., Warren E.F., Leis S.M., et al. Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol 2004, 38:475-483.
9. Eiseman B., Silen W., Bascom G.S., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958, 44:854-859.
10. Cutolo L.C., Kleppel N.H., Freund R.H., et al. Fecal feedings as a therapy in Staphylococcus enterocolitis. N Y State J Med 1959, 59:3831-3833.
11. Fenton S., Stephenson D., Weder C., et al. Pseudomembranous colitis associated with antibiotic therapy-an emerging entity. Can Med Assoc J 1974, 111:1110-1114.
12. Bowden T.A., Mansberger A.R., Lykins L.E. Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. Am Surg 1981, 47:178-183.
13. Schwan A., Sjölin S., Trottestam U., et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984, 16:211-215.
14. Tvede M., Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989, 1:1156-1160.
15. Flotterod O., Hopen G. Tidsskr Nor Laegeforen 1991, 111:1364-1365. [in Norwegian].
16. Paterson D.L., Iredell J., Whitby M. Putting back the bugs: bacterial treatment relieves chronic diarrhoea. Med J Aust 1994, 160:232-233.
17. Harkonen N. Recurrent pseudomembranous colitis treated with the donor feces. Duodecim 1996, 112:1803-1804.
18. Lund-Tonneson S., Berstad A., Schreiner A., et al. Tidsskr Nor Laegeforen 1998, 118:1027-1030. [in Norwegian].
19. Persky S.E., Brandt L.J. Treatment of recurrent Clostridium difficile-associated diarrhoea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000, 95:3283-3285.
20. Faust G., Langelier D., Haddad H., et al. Treatment of recurrent pseudomembranous colitis (RPMC) with stool transplantation (ST): report of six (6) cases. Can J Gastroenterol 2002, a002.
21. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003, 36:580-585.
22. Jorup-Rönström C., Hakanson A., Persoon A.K. Larkartidningen 2006, 103:3603-3605. [abstract], [in Swedish].
23. Wettstein A, Borody TJ, Leis S. Fecal bacteriotherapy-an effective treatment for relapsing symptomatic Clostridium difficile infection [abstract G67]. Presented at the 15th United European Gastroenterology Week. 2007.
24. Louie TJ. Home-based fecal flora infusion to arrest multiple-recurrent Clostridium difficile infection (CDI). Presented at the 48th Interscience Conference on Antimicrobial Agents, Chemotherapy in conjunction with the Infectious Disease Society of America. 2008.
25. Niewdorp M., Van Nood E., Speelman P., et al. Ned Tijdschr Geneeskd 2008, 152:1927-1932. [in dutch].
26. You D.M., Franzos M.A., Holman R.P. Successful treatment of fulminant Clostridium difficile infection with fecal bacteriotherapy. Ann Intern Med 2008, 148:632-633.
27. Hellemans R., Naegels S., Holvoet J. Faecal transplantation for recurrent Clostridium difficile colitis, an underused treatment modality. Acta Gastroenterol Belg 2009, 72:269-270.
28. MacConachie A.A., Fox R., Kennedy D.R., et al. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009, 102:781-784.
29. Arkkila P.E., Uusitalo-Seppälä R., Lehtola L., et al. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Gastroenterology 2010, 138:S5.
30. Khoruts A., Dicksved J., Jansson J.K., et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol 2010, 44:354-360.
31. Yoon S.S., Brandt L.J. Treatment of refractory/recurrent C. difficile-associated disease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010, 44:562-566.
32. Rohlke F., SUrawicz C.M., Stollman N. Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin Gastroenterol 2010, 44:567-570.
33. Silverman M.S., Davis I., Pillai D.R. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010, 5:471-473.
34. Garborg K., Waagsbó B., Stallemo A., et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010, 42:857-861.
35. Russel G., Kaplan J., Ferraro M.J., et al. Fecal bacteriotherapy for relapsing Clostridium difficile infection in a child: a proposed treatment protocol. Pediatrics 2010, 126:e239-e242.
36. Kelly C., De Leon L. Successful treatment of recurrent Clostridium difficile infection with donor stool administered at colonoscopy: a case series. Am J Gastroenterol 2010, 105:S135. [abstract 366].
37. Mellow M., Kanatzar A. Colonoscopic fecal bacteriotherapy in the treatment of recurrent Clostridium difficile infection. Am J Gastroenterol 2010, 105:S135. [abstract].
38. Kassam Z., Hundal R., Marshall J.K., et al. Fecal transplantation via retention enemas is effective for recurrent or refractory Clostridium difficile-associated diarrhea. Gastroenterology 2010, 138:S207-S208.
39. Kelly C.R., de Leon L., Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 2012, 46(2):145-149.
40. Hamilton M.J., Weingarden A.R., Sadowsky M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107(5):761-767.
41. Mattila E., Uusitalo-Seppälä R., Wuorela M., et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012, 142(3):490-496.
42. Brandt L.J., Aroniadis O.C., Mellow M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 2012, 107(7):1079-1087.
43. Pepin J., Valiquette L., Alary M.E., et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-472.
44. Niagara System Faces Government Control. CBC news. Available at: http://www.cbc.ca/news/health/story/2011/08/15/c-difficile-niagara-supervisor.html.
45. Sailhamer E.A., Carson K., Chang Y., et al. Fulminant Clostridium difficile colitis. Arch Surg 2009, 144(5):433-439.
46. Pepin J. Improving the treatment of Clostridium difficile-associated disease: where should we start?. Clin Infect Dis 2006, 43:553-555.
47. McFarland L.V., Elmer G.W., Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002, 97:1769-1775.
48. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 2006, 145(10):758-764.
49. Louie T.J., Miller M.A., Mullane K.M., et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011, 364(5):422-431.
50. Lagrotteria D., Holmes S., Smieja M., et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006, 43(5):547-552.
51. Apisarnthanarak A., Mundy L.M. Intracolonic vancomycin for adjunctive treatment of severe clostridium difficile colitis: indications and precautions. J Infect Dis Antimicrob Agents 2005, 22:21-26.
52. McFarland L.V. Alternative treatments for Clostridium difficile disease: what really works?. J Med Microbiol 2005, 54(2):101-111.
53. Tolevamer: a novel, non-antibiotic drug being investigated for the treatment of the most common cause of nosocomial diarrhea. Available at: http://www.genzyme.com/corp/./genz_pdf_tolevamer_nonconfidential.pdf.
54. Riley T.V., Thean S., Hool G., et al. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009, 190(12):706-708.
55. Richards M., Knox J., Elliott B., et al. Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Med J Aust 2011, 194(7):369-371.
56. State hospitals fall prey to a different superbug. Available at: http://www.theage.com.au/victoria/state-hospitals-fall-prey-to-a-difficult-superbug-20120525-1zads.html.
57. Grehan M.J., Leis S.M., Campbell J., et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol 2010, 44:551-561.
58. Brandt L.J., Borody T.J., Campbell J. Endoscopic fecal microbiota transplantation ''first-line'' treatment for severe Clostridium difficile Infection?. J Clin Gastroenterol 2011, 45(8):655-657.
59. Fujimura K.E., Slusher N.A., Cabana M.D., et al. Role of the gut microbiota in defining human health. Expert Rev Anti Infect Ther 2010, 8(4):435-454.
60. Qin J., Ruiqiang L., Raes J., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65.
61. Backhed F., Ley R.E., Sonnenburg J.L., et al. Host-bacterial mutualism in the human intestine. Science 2005, 307(5717):1915-1920.
62. Sekirov I., Russell S.L., Antunes C.M., et al. Gut microbiota in health and disease. Physiol Rev 2010, 90(3):859-904.
63. Van Der Waaj D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982, 10:263-270.
64. Barna J.C., Williams D.H. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu Rev Microbiol 1984, 38:339-357.
65. Le Blay G., Lacroix C., Zihler A., et al. In vitro inhibition activity of nisin A, nisin Z, pediocin PA-1 and antibiotics against common intestinal bacteria. Lett Appl Microbiol 2007, 45(3):252-257.
66. Martinez-Medina M., Aldeguer X., Gonzalez-Huix F., et al. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm Bowel Dis 2006, 12(12):1136-1145.
67. Fava F., Danese S. Intestinal microbiota in inflammatory bowel disease: friend or foe?. World J Gastroenterol 2011, 17(5):557-566.
68. Sokol H., Pigneur B., Watterlot L., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn's disease patients. Proc Natl Acad Sci U S A 2008, 105(43):16731-16736.
69. Lupp C., Robertson M.L., Wickham M.E., et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2007, 2(3):204.
70. Barman M., Unold D., Shifley K., et al. Enteric salmonellosis disrupts the microbial ecology of the murine gastrointestinal tract. Infect Immun 2008, 76(3):907-915.
71. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
72. Campbell J., Borody T.J., Leis S. The many faces of Crohn's Disease: latest concepts in etiology. Open J Intern Med 2012, [Epub ahead of print].
73. Borody T.J., George L., Andrews P., et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust 1989, 150:604.
74. Moussata D., Goetz M., Gloeckner A., et al. Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut 2011, 60:26-33.
75. Andrews P.J., Barnes P., Borody T.J. Chronic constipation reversed by restoration of bowel flora. A case and a hypothesis. Eur J Gastroenterol Hepatol 1992, 4:245-247.
76. Turnbaugh P.J., Ley R.E., Mahowald M.A., et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444:1027-1031.
77. Larsen N., Vogensen F.K., Van Den Berg F.W., et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010, 5(2):e9085.
78. Parracho H., Bingham M.O., Gibson G.R., et al. Differences between the gut microflora of children with autism spectrum disorders and that of healthy children. J Med Microbiol 2005, 54(10):987-991.
79. Gower-Rousseau C., Reumaux D., Bellard M., et al. Remission of myasthenia gravis after proctocolectomy in a patient with ulcerative colitis. Am J Gastroenterol 1993, 88(7):1136-1138.
80. Edwards C.J. Commensal gut bacteria and the etiopathogenesis of rheumatoid arthritis. J Rheumatol 2008, 35:1477-1479.
81. Armougom F., Henry M., Vialettes B., et al. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and methanogens in anorexic patients. PLoS One 2009, 4(9):e7125.
82. Ley R.E., Backhed F., Turnbaugh P., et al. Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A 2005, 102(31):11070-11075.
83. Vrieze A., Holleman F., Serlie M.J., et al. Metabolic effects of transplanting gut microbiota from lean donors to subjects with metabolic syndrome. EASD 2010, A90.
84. Ueki A., Otsuka M. Life style risks of Parkinson's disease: association between decreased water intake and constipation. J Neurol 2004, 251(7):18-23.
85. Abbott R.D., Petrovich H., White L.R., et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001, 57:456-462.
86. Borody T.J., Torres M., Campbell J., et al. Treatment of severe constipation improves Parkinson's Disease (PD) symptoms. Am J Gastroenterol 2009, S999.
87. Braak H., Del Tredechi K., Rüb U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24:197-211.
88. Borody T.J., Rosen D.M., Torres M., et al. Myoclonus dystonia- affected by GI microbiota. Am J Gastroenterol 2011, 106:S352.
89. Mazmanian S.K., Liu C.H., Tzianabos A.O., et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005, 122:107-118.
90. Finegold S., Molitoris D., Song Y., et al. Gastrointestinal microflora studies in late-onset autism. Clin Infect Dis 2002, 35:S6-16.
91. Finegold S. State of the art; microbiology in health and disease. Intestinal bacterial flora in autism. Anaerobe 2011, 17:367-368.
92. Goodwin M.S., Goodwin T.C., Cowen M.A. Malabsorption and cerebral dysfunction: a multivariate and comparative study of autistic children. J Autism Child Schizophr 1971, 1(1):48-62.
93. Horvath K., Perman J.A. Autism and gastrointestinal symptoms. Curr Gastroenterol Rep 2002, 4(3):251-258.
94. Valicenti-McDermott M., McVicar K., Rapin I., et al. Frequency of gastrointestinal symptoms in children with autism spectrum disorders and association with family history of autoimmune disease. J Dev Behav Pediatr 2006, 27:S128-S136.
95. Song Y., Liu C., Finegold S.M. Real-time PCR quanititation of clostridia in feces of autistic children. Appl Environ Microbiol 2004, 70(11):6459-6465.
96. Sandler R.H., Finegold S.M., Bolte E.R., et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000, 15(7):429-435.
97. Ziomber A., Juszczak K., Kaszuba-Zwionska J., et al. Magnetically induced vagus nerve stimulation and feeding behaviour in rats. J Physiol Pharmacol 2009, 60(3):71-77.
98. Bravo J.A., Forsythe P., Chew M.V. Ingestion of Lactobacillus strain regulates emotional behaviour and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011, 108(38):16050-16055.
99. McLean P.G., Bergonzelli G.E., Collins S.M., et al. Targeting the microbiota-gut-brain axis to modulate behaviour: which bacterial strain will translate best to humans?. Proc Natl Acad Sci U S A 2012, 109(4):E174.
100. Bolte E.R. Autism and clostridium tetani. Med Hypothesis 1998, 51(2):133-144.
101. Borody TJ. Bacteriotherapy for chronic fatigue syndrome: a long-term follow up study. Presented at the 1995 CFS National Consensus Conference.
102. FDA AABB donor history questionnaire documents. Available at: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/BloodDonorScreening/UCM213552.pdf.
103. Aas J., Gessert C.E., Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2002, 34(3):346-353.